OncoSil Medical completes $2.1M manufacturing validation

• OncoSil Medical completed three manufacturing validation cycles with its partner Cyclotek.
• The announcement coincided with the company's share price rising to $1.40.
• The company expects this validation to improve its gross margins and support future global commercial demand.

OncoSil Medical (ASX:OSL) completed three manufacturing validation cycles to establish a local production capability for over 50 device doses.

This milestone follows a total capital investment of approximately $2.1 million into dedicated manufacturing equipment owned by the business.

"This model strengthens our control over quality, supply and manufacturing capability while supporting improved margins and positioning the company to meet growing global commercial demand," said OncoSil Medical CEO & Managing Director Nigel Lange.

The company stated that commercial production is expected to commence in the second half of 2026, subject to regulatory inspection and approval.

Following the announcement, the OncoSil Medical share price was up at $1.40.

The medical device company focuses on localised treatments for patients with unresectable locally advanced pancreatic cancer.

The manufacturing expansion aims to de-risk a key component of the company's broader commercial strategy.